Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2008

01-11-2008 | Gastrointestinal Oncology

Clinical Significance of Circulating Tumor Cells in Blood from Patients with Gastrointestinal Cancers

Authors: Kunihiko Hiraiwa, MD, Hiroya Takeuchi, MD, PhD, Hirotoshi Hasegawa, MD, PhD, Yoshiro Saikawa, MD, PhD, Koichi Suda, MD, PhD, Takashi Ando, MD, Koshi Kumagai, MD, Tomoyuki Irino, MD, Takahisa Yoshikawa, MD, Sachiko Matsuda, PhD, Masaki Kitajima, MD, PhD, Yuko Kitagawa, MD, PhD

Published in: Annals of Surgical Oncology | Issue 11/2008

Login to get access

Abstract

Background

Circulating tumor cells (CTCs) measured by the CellSearch system in metastatic breast cancer have been reported to correlate with shorter overall survival. The purpose of this study was to clarify the clinicopathologic characteristics of CTCs in gastrointestinal cancers.

Methods

Pre- and postoperative CTCs from 130 gastrointestinal cancer patients and 41 healthy volunteers were measured by this system. Correlation between CTC counts and clinicopathologic variables was examined.

Results

The number of CTCs in metastatic patients (n = 79) was larger than in nonmetastatic patients (n = 35) and in healthy donors (n = 41) (P < 0.001). CTC counts were larger in metastatic gastric cancer (n = 27) than in nonmetastatic gastric cancer (n = 14) (P = 0.016). Two or more CTCs was significantly correlated with advanced tumor stage in all gastrointestinal cancers (P < 0.001) and in gastric cancer (P = 0.032). Two or more CTCs had significant correlation with peritoneal dissemination of gastric or colorectal cancer (P = 0.007) and pleural dissemination of esophageal cancer (P = 0.033). The survival of patients with ≥2 CTCs was shorter than that of patients with <2 CTCs (P = 0.005). The change in CTCs tended to correlate with disease progression and chemotherapeutic effect.

Conclusion

This study suggests that measurement of CTCs in gastrointestinal cancer patients could be useful as a tool for judging tumor stage, predicting the presence of peritoneal or pleural dissemination and patients’ survival, and monitoring response to cancer therapy.
Literature
1.
Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998;95:4589–94PubMedCrossRef
2.
Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 1999;5:1950–60PubMed
3.
Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003;107:984–90PubMedCrossRef
4.
Molnar B, Ladanyi A, Tanko L, et al. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001;7:4080–5PubMed
5.
Witzig TE, Bossy B, Kimlinger T, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002;8:1085–91PubMed
6.
Mehes G, Witt A, Kubista E, et al. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001;159:17–20PubMed
7.
Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004;10:1392–400PubMedCrossRef
8.
Fehm T, Sagalowsky A, Clifford E, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002;8:2073–84PubMed
9.
Shariat SF, Roudier MP, Wilcox GE, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 2003;63:4662–70PubMed
10.
Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:165–73PubMed
11.
Straub B, Muller M, Krause H, et al. Quantitative real-time RT-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients. Oncology 2003;65:12–7PubMedCrossRef
12.
Gao CL, Rawal SK, Sun L, et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res 2003;9:2545–50PubMed
13.
Moreno JG, O’Hara SM, Gross S, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001;58:386–92PubMedCrossRef
14.
Hamdy FC, Lawry J, Anderson JB, et al. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 1992;69:392–6PubMed
15.
Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897–904PubMedCrossRef
16.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–91PubMedCrossRef
17.
Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420–30PubMedCrossRef
18.
Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218–24PubMedCrossRef
19.
Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403–9PubMedCrossRef
20.
Cohen SJ, Alpaugh RK, Gross S, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:125–32PubMedCrossRef
21.
Schroder CP, Ruiters MH, de Jong S, et al. Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer 2003;106:611–8PubMedCrossRef
22.
de Cremoux P, Extra JM, Denis MG, et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 2000;6:3117–22PubMed
23.
De Luca A, Pignata S, Casamassimi A, et al. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clin Cancer Res 2000;6:1439–44PubMed
24.
Sakakura C, Hagiwara A, Nakanishi M, et al. Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer 2002;87:1153–61PubMedCrossRef
25.
Heiss MM, Strohlein MA, Jager M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435–43PubMedCrossRef
26.
Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899–905PubMedCrossRef
Metadata
Title
Clinical Significance of Circulating Tumor Cells in Blood from Patients with Gastrointestinal Cancers
Authors
Kunihiko Hiraiwa, MD
Hiroya Takeuchi, MD, PhD
Hirotoshi Hasegawa, MD, PhD
Yoshiro Saikawa, MD, PhD
Koichi Suda, MD, PhD
Takashi Ando, MD
Koshi Kumagai, MD
Tomoyuki Irino, MD
Takahisa Yoshikawa, MD
Sachiko Matsuda, PhD
Masaki Kitajima, MD, PhD
Yuko Kitagawa, MD, PhD
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0122-9

Other articles of this Issue 11/2008

Annals of Surgical Oncology 11/2008 Go to the issue

Breast Oncology

Translation Initiation Factor 4E (eIF4E): Prognostic Marker and Potential Therapeutic Target

Breast Oncology

A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer

Gastrointestinal Oncology

Extrahepatic Bile Duct Adenocarcinoma: Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone

Breast Oncology

Axillary Reverse Mapping in Breast Cancer: A New Microsurgical Lymphatic–Venous Procedure in the Prevention of Arm Lymphedema

Other

A Statewide Community Cancer Center Videoconferencing Program

Gastrointestinal Oncology

Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse